Contributions
Abstract: PB1512
Type: Publication Only
Session title: Chronic myeloid leukemia - Biology & Translational Research
Background
The emergence of inhibitors of atypical tyrosine kinase changed the prognosis of the course of the disease in patients with CML. This type of therapy is comparable to allogeneic hematopoietic stem cell transplantation in terms of efficiency, and radically surpasses it in terms of safety. The success of imatinib therapy may be partly due to the increase in average telomere length. Recent studies have shown a permanent decrease in telomere length in CML patients in sustained complete cytogenetic remission, virtually regardless of what therapy was used to induce remission. This finding may indicate a pre-existing shortage of telomere length in CML patients (and a potential predisposition to CML) prior to the development of BCR / ABL positive hematopoiesis.
Aims
to reseche the dependence of the length telomeric fragments of chromosome on the presence of chronic myeloid leukemia in the person.
Methods
We have studied of the length telomeric fragments of chromosome in a group of 27 patients with chronic myeloid leukemia. The group was consisted of 15 women (55.6%), average age 53.93 years and 12 men (44.4%), average age 50.54 years. The group of women was more homogeneous: 5 patients achieved a major molecular response (MMR), 3 - only a cytogenetic response (CR), MMR have not obtained, and 4 patients were newly diagnosed in the chronic phase of the disease. In the group of men, MMR was achieved in 1 patient, only CR - in 2, chronic phase, no CR was obtained in 3, primary patients in the chronic phase - 3 and progressive phase of the disease, terminal stage (blast crisis) - in 3 patients. The study of telomere length have stadied out on DNA material isolated from blood cells using quantitative PCR (qPCR) in real time based on the method of R.T. Cawthon et al. (2002) with modifications.
Results
The average level of blood telomere length (TL) was 1.185 ± 1.037 (min. 0.188 / max. 5.681, median 0.960) in the group of CML patients, and 1.388 ± 0.417 (min. 0.440 / max. 2.780, median 1.340) in the group of subjects without hemoblastosis. , that is, the length of blood telomeres was shorter in patients with CML. According to the one-sample Kolmogorov-Smirnov test, the distribution did not correspond to the normal one; therefore, nonparametric tests were used for comparison. We have compared telomere lengths separately in the groups of women and men with CML and men and women from the comparison group. The length of leukocyte telomeres was significantly less in the group of women with CML, compared to the control (p <0.001; asymptotic significance (2-sided) in the Mann-Whitney test). There were no significant differences in men. In women with CML, TL 0.984 ± 0.552 (median 0.917), in the control group TL 1.442 ± 0.426) (median 1.376). In men with CML TL was 1.419 ± 1.405 (median 1.047), in the control group TL 1.317 ± 0.397 (median 1.287). The presence of an aggressive clone of lecosis cells in men with progressive stages of CML can explain the absence of significant differences and even the excess of TL (1.419 ± 1.405) compared with the control group (1.317 ± 0.397). At the same time, the median TL in men with CML is less than in the control group (1.047 and 1.287, respectively).
Conclusion
Investigation of telomere length is an important diagnostic technique in determining the predisposition to the development of CML and determining the prognosis of the deasese
Keyword(s): Chronic myeloid leukemia, Telomere length
Abstract: PB1512
Type: Publication Only
Session title: Chronic myeloid leukemia - Biology & Translational Research
Background
The emergence of inhibitors of atypical tyrosine kinase changed the prognosis of the course of the disease in patients with CML. This type of therapy is comparable to allogeneic hematopoietic stem cell transplantation in terms of efficiency, and radically surpasses it in terms of safety. The success of imatinib therapy may be partly due to the increase in average telomere length. Recent studies have shown a permanent decrease in telomere length in CML patients in sustained complete cytogenetic remission, virtually regardless of what therapy was used to induce remission. This finding may indicate a pre-existing shortage of telomere length in CML patients (and a potential predisposition to CML) prior to the development of BCR / ABL positive hematopoiesis.
Aims
to reseche the dependence of the length telomeric fragments of chromosome on the presence of chronic myeloid leukemia in the person.
Methods
We have studied of the length telomeric fragments of chromosome in a group of 27 patients with chronic myeloid leukemia. The group was consisted of 15 women (55.6%), average age 53.93 years and 12 men (44.4%), average age 50.54 years. The group of women was more homogeneous: 5 patients achieved a major molecular response (MMR), 3 - only a cytogenetic response (CR), MMR have not obtained, and 4 patients were newly diagnosed in the chronic phase of the disease. In the group of men, MMR was achieved in 1 patient, only CR - in 2, chronic phase, no CR was obtained in 3, primary patients in the chronic phase - 3 and progressive phase of the disease, terminal stage (blast crisis) - in 3 patients. The study of telomere length have stadied out on DNA material isolated from blood cells using quantitative PCR (qPCR) in real time based on the method of R.T. Cawthon et al. (2002) with modifications.
Results
The average level of blood telomere length (TL) was 1.185 ± 1.037 (min. 0.188 / max. 5.681, median 0.960) in the group of CML patients, and 1.388 ± 0.417 (min. 0.440 / max. 2.780, median 1.340) in the group of subjects without hemoblastosis. , that is, the length of blood telomeres was shorter in patients with CML. According to the one-sample Kolmogorov-Smirnov test, the distribution did not correspond to the normal one; therefore, nonparametric tests were used for comparison. We have compared telomere lengths separately in the groups of women and men with CML and men and women from the comparison group. The length of leukocyte telomeres was significantly less in the group of women with CML, compared to the control (p <0.001; asymptotic significance (2-sided) in the Mann-Whitney test). There were no significant differences in men. In women with CML, TL 0.984 ± 0.552 (median 0.917), in the control group TL 1.442 ± 0.426) (median 1.376). In men with CML TL was 1.419 ± 1.405 (median 1.047), in the control group TL 1.317 ± 0.397 (median 1.287). The presence of an aggressive clone of lecosis cells in men with progressive stages of CML can explain the absence of significant differences and even the excess of TL (1.419 ± 1.405) compared with the control group (1.317 ± 0.397). At the same time, the median TL in men with CML is less than in the control group (1.047 and 1.287, respectively).
Conclusion
Investigation of telomere length is an important diagnostic technique in determining the predisposition to the development of CML and determining the prognosis of the deasese
Keyword(s): Chronic myeloid leukemia, Telomere length